|Country:||Switzerland and Germany|
|Category:||Emerging Biotech Company|
|Date:||April 25, 2023|
|Speaker:||Leila Jaafar, CEO|
NUCLIDIUM is setting a new standard in the precision oncology landscape by developing best-in-class copper-based radiopharmaceuticals that enable the highest accuracy and accessibility for targeted cancer treatment and diagnosis. We leverage the unique properties of copper to achieve an improved safety and efficacy profile with advantageous economics and secured supply for hospitals and patients.